Moomoo AI 已提取核心訊息
On February 5, 2024, Exicure, Inc., a biotechnology company known for developing nucleic acid therapies, announced a patent license agreement with Bluejay Therapeutics, Inc., a private biopharmaceutical company. The agreement grants Bluejay an exclusive license to use Exicure's patents for developing cavrotolimod as a potential treatment for hepatitis. Bluejay made an initial payment to Exicure and will also pay royalties on future net sales of any licensed technology. Exicure retains responsibility for patent maintenance and prosecution. CEO Paul Kang highlighted the partnership's alignment with Exicure's strategic shift towards maximizing shareholder value following a restructuring and suspension of clinical activities. The company is exploring strategic alternatives for its biotechnology assets.
On February 5, 2024, Exicure, Inc., a biotechnology company known for developing nucleic acid therapies, announced a patent license agreement with Bluejay Therapeutics, Inc., a private biopharmaceutical company. The agreement grants Bluejay an exclusive license to use Exicure's patents for developing cavrotolimod as a potential treatment for hepatitis. Bluejay made an initial payment to Exicure and will also pay royalties on future net sales of any licensed technology. Exicure retains responsibility for patent maintenance and prosecution. CEO Paul Kang highlighted the partnership's alignment with Exicure's strategic shift towards maximizing shareholder value following a restructuring and suspension of clinical activities. The company is exploring strategic alternatives for its biotechnology assets.
2024年2月5日，以開發核酸療法而聞名的生物技術公司Exicure, Inc. 宣佈與私營生物製藥公司Bluejay Therapeutics, Inc. 簽訂專利許可協議。該協議授予Bluejay獨家許可，允許其使用Exicure的專利開發卡夫羅莫德作爲肝炎的潛在治療方法。Bluejay向Exicure支付了首筆款項，還將爲任何許可技術的未來淨銷售額支付特許權使用費。Exicure保留專利維護和起訴的責任。首席執行官保羅·康強調，該合作伙伴關係與Exicure在重組和暫停臨床活動後向實現股東價值最大化的戰略轉變一致。該公司正在爲其生物技術資產探索戰略替代方案。
2024年2月5日，以開發核酸療法而聞名的生物技術公司Exicure, Inc. 宣佈與私營生物製藥公司Bluejay Therapeutics, Inc. 簽訂專利許可協議。該協議授予Bluejay獨家許可，允許其使用Exicure的專利開發卡夫羅莫德作爲肝炎的潛在治療方法。Bluejay向Exicure支付了首筆款項，還將爲任何許可技術的未來淨銷售額支付特許權使用費。Exicure保留專利維護和起訴的責任。首席執行官保羅·康強調，該合作伙伴關係與Exicure在重組和暫停臨床活動後向實現股東價值最大化的戰略轉變一致。該公司正在爲其生物技術資產探索戰略替代方案。
有用
沒用